Polar Asset Management Partners’s Apellis Pharmaceuticals APLS Stock Holding History

Polar Asset Management Partners’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-32,200	Closed	-$1.89M	–	710
2024 Q1	$1.89M	Buy	+32,200	New	+$2.05M	0.03%	367
2023 Q3	–	Sell	-105,810	Closed	-$9.64M	–	871
2023 Q2	$9.64M	Buy	105,810 +6,600	+7%	+$569K	0.17%	155
2023 Q1	$6.54M	Buy	99,210 +40,900	+70%	+$2.36M	0.1%	270
2022 Q4	$3.02M	Sell	58,310 -324,290	-85%	-$17.2M	0.04%	551
2022 Q3	$26.1M	Buy	382,600 +292,300	+324%	+$17.3M	0.31%	45
2022 Q2	$4.08M	Buy	90,300 +42,100	+87%	+$1.92M	0.05%	543
2022 Q1	$2.45M	Sell	48,200 -38,400	-44%	-$1.7M	0.03%	591
2021 Q4	$4.09M	Buy	86,600 +58,600	+209%	+$2.31M	0.04%	460
2021 Q3	$923K	Buy	+28,000	New	+$1.57M	0.01%	709

Other funds holding APLS

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Polar Asset Management Partners's APLS Position: Q2 2024 in Review

Polar Asset Management Partners sold out of Apellis Pharmaceuticals (APLS) in Q2 2024, closing a stake of 32,200 shares — an estimated $1.89M sold.

Polar Asset Management Partners first reported a position in APLS in Q3 2021 and held it in 9 quarters. The position peaked at $26.1M in Q3 2022. 263 funds tracked by Wall St. Rank hold APLS as of Q2 2024.

Polar Asset Management Partners reported no remaining Apellis Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Polar Asset Management Partners sold 32,200 Apellis Pharmaceuticals shares in Q2 2024, an estimated $1.89M.
Polar Asset Management Partners first reported a position in Apellis Pharmaceuticals in Q3 2021 and held it in 9 quarters.
Polar Asset Management Partners's Apellis Pharmaceuticals position peaked at $26.1M in Q3 2022.
263 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2024.

Based on Polar Asset Management Partners's 13F filing for Q2 2024, filed 14 Aug 2024.